Capsular contracture is a condition where the scar tissue that naturally forms around a breast implant thickens, tightens, and squeezes the implant. It’s the most common complication of breast implant surgery, affecting roughly 5% to 19% of augmentation patients depending on the study and follow-up period. In mild cases, you might not notice anything at all. In severe cases, the breast becomes visibly distorted, feels hard, and can be painful.
Why the Body Forms a Capsule
Every time a foreign object is placed in the body, the immune system responds by building a wall of collagen fibers around it. This is normal and expected. After breast implant surgery, a thin, flexible capsule forms around the implant within weeks. In most people, this capsule stays soft and pliable, and you’d never know it was there.
Capsular contracture happens when that process goes into overdrive. A signaling molecule called TGF-beta acts as the master switch for scar tissue production. When it stays active too long or becomes overactive, it triggers certain cells called myofibroblasts to multiply and produce excessive collagen. These myofibroblasts also contain contractile fibers, similar to muscle cells, which physically squeeze the capsule tighter. In lab studies, exposure to TGF-beta increased collagen production and contractile fiber activity by 2 to 10 times above normal levels. The result is a capsule that keeps thickening and shrinking around the implant instead of settling into a stable, soft layer.
What Triggers It
No single cause explains every case, but several factors are well established. One of the leading theories involves bacterial biofilm, a thin, invisible layer of bacteria that can colonize the implant surface during or after surgery. Unlike a full-blown infection with obvious redness and fever, biofilm sits at a low level that doesn’t produce clear symptoms but keeps the immune system in a constant state of alert. This prolonged inflammatory response continuously recruits immune cells to the area, which in turn drives more scar tissue formation. The body essentially never stops trying to fight off the bacteria, and the capsule keeps getting thicker as a consequence.
Implant placement matters significantly. In one comparative review, the capsular contracture rate was 58% when implants were placed above the chest muscle (subglandular) versus 9.4% when placed beneath it (submuscular). The muscle layer appears to provide a buffer that reduces inflammation and limits bacterial migration from breast tissue to the implant surface.
Radiation therapy is another major trigger. Ionizing radiation activates the same TGF-beta pathway, pushing fibroblasts into overdrive and leading to excessive scar tissue. Patients who receive radiation after breast reconstruction face a notably higher risk. Other contributing factors include bleeding around the implant (hematoma), silicone gel leakage from a ruptured implant, and the implant’s surface texture.
How Surface Texture Affects Risk
The relationship between smooth and textured implants is less clear-cut than many sources suggest. Some data assigns a 15% contracture risk to smooth, round implants and about 5% to textured devices. But a large manufacturer study with 10-year follow-up reported an 18.9% contracture rate for augmentation patients with no significant difference between smooth and textured implants. A separate study found similar low rates for both types when placed under the muscle: 1.6% for smooth and 3.3% for textured, a difference that wasn’t statistically meaningful.
More recently, very lightly textured “nanotextured” implants have shown contracture rates as low as 1%, though long-term data is still accumulating. The texture debate is further complicated by safety concerns around heavily textured implants and their association with a rare lymphoma, which has led many surgeons to shift back toward smooth or lightly textured options.
Symptoms and When They Appear
Capsular contracture most commonly develops between one and two years after surgery, though it can appear earlier or much later. Cases appearing within the first six months are considered early onset and are relatively uncommon. In documented early cases, patients reported symptoms as soon as nine weeks after surgery, including pain, redness, heaviness extending to the back and shoulder, and visible changes in breast shape.
The progression typically follows a recognizable pattern. You might first notice that one breast feels slightly firmer than the other, or that the implant no longer moves freely when you shift position. As the capsule tightens further, the breast starts to look rounder and higher than normal. In advanced stages, the breast takes on a ball-like shape, feels hard to the touch, and becomes painful. The cosmetic distortion can be obvious even through clothing.
How It’s Graded
Doctors classify capsular contracture using the Baker grading system, which has been the standard since 1978. It evaluates how the breast looks, how it feels, and whether there’s pain.
- Grade I: The breast looks and feels natural. The capsule is flexible and thin (half a millimeter or less on ultrasound). Most implant patients have a Grade I capsule and never need treatment.
- Grade II: The breast looks normal but feels slightly firm. You or your surgeon can tell the implant is there by touch, though there’s no visible distortion.
- Grade III: The breast feels noticeably firm and appears visibly abnormal. The shape may look too round, too high, or asymmetric compared to the other side. The capsule is typically 1.5 millimeters or thicker with visible wrinkling on imaging.
- Grade IV: The breast is hard, painful, and clearly distorted. On ultrasound, the capsule is thick with both abnormal wrinkling and shape deformity. This stage almost always requires surgical correction.
Grades I and II generally don’t require intervention. Grades III and IV are where treatment becomes necessary, either for comfort, appearance, or both.
Non-Surgical Treatment
For mild to moderate contracture (Baker II or early III), some plastic surgeons prescribe leukotriene antagonists, medications originally developed for asthma that block inflammatory pathways involved in scar tissue formation. These are used off-label, meaning they’re not formally approved for this purpose, but clinical experience suggests they can soften early-stage contracture. In one preliminary study, patients with mild contracture (below Baker III) showed better improvement than those with more severe cases. The medications are generally well tolerated with minimal side effects.
Massage and compression techniques are also commonly recommended after surgery as preventive measures, though their effectiveness is debated. Once a capsule has progressed to a firm, symptomatic stage, non-surgical approaches become much less likely to resolve the problem.
Surgical Options
When contracture reaches Grade III or IV, surgery is typically the path forward. Two main approaches exist, and they differ significantly in scope and recovery.
A capsulotomy involves cutting into the thickened capsule to release the tension without removing it. The surgeon makes incisions through the scar tissue, allowing the implant more room. This is a faster procedure, usually taking 20 to 30 minutes per side, with patients returning to normal activities within a few days. For thin, non-calcified capsules, leaving the tissue in place rarely causes problems. Fluid accumulation (seroma) occurred in only 1.3% of cases in one study.
A capsulectomy involves removing part or all of the capsule itself. This adds roughly an hour of operating time per side and requires significantly more dissection. It carries higher risks of bleeding, nerve injury, and in rare cases, puncture of the lung lining when removing tissue from the chest wall. A drain may be needed afterward. Capsulectomy is generally reserved for thick, calcified capsules or cases where leaving the tissue behind isn’t advisable. Many surgeons combine capsulectomy with switching the implant to a new pocket (for example, moving from above the muscle to below it) and replacing the implant entirely.
Risk of Recurrence
One of the most frustrating aspects of capsular contracture is that it can come back. The recurrence rate after revision surgery is roughly double that of a first-time augmentation. Studies of large patient cohorts show a 5% to 7% incidence after primary augmentation over seven years, compared to 12% to 18% after revision surgery. For breast reconstruction patients, primary rates run 9% to 13%, climbing to 10% to 18% after revision.
To reduce recurrence, some surgeons now use acellular dermal matrix, a processed tissue graft that acts as a barrier between the implant and the surrounding capsule. It appears to interrupt the inflammatory cycle that drives contracture. In pooled data from multiple studies, one widely used product reduced the risk of capsular contracture by 86% compared to conventional treatment, with an overall contracture rate of just 1.53%. This approach is becoming increasingly common in revision surgeries for patients with a history of recurrent contracture.